Wed, Aug 27, 2014, 6:32 AM EDT - U.S. Markets open in 2 hrs 58 mins


% | $
Quotes you view appear here for quick access.

Cytori Therapeutics, Inc. Message Board

  • rhdapeng rhdapeng Feb 16, 2009 8:32 AM Flag

    how good is CYTX patent protection

    BHRT (bioheart) seems to be selling the same, or a very similar, machine as cytori. i.e. take adipose tissue and deliver stem cells in 1 hour. Is the design of the device so simple that it will be easily varied sufficiently to bypass patent protection, and so there will be lots of competitors crawling out, or is CYTX not enforcing its patents?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Good point.

      The device you are referring to is the TGI 1200 from a tiny outfit from Hawaii, who sold the rights to develop the therapies based on extraction from adipose tissue of "endothelial cells" to BioHeart. The technology is based on extremely old Williams patents.

      In my mind there are very few endothelial cells in adipose tissue, but nonetheless, they are continuing development, which I have also put forward to Cytori more than 2 years ago.

      Apparently they are taking a wait and see approach- expecting natural "extinction"- but you might want to ask IR again what the status to date is.

      In my mind CYTX is protected in an excellent way by the latest issued patents on Celution and the applications either patented or in process of application for patent.

    • BHRT...when they came public I recommended them as a short on this board.
      If you look at the company, they need life support themselves.
      BHRT does NOT use adipose derived stem cells, rather BHRT uses muscle derived stem cells.
      CYTX has strong patent protection for its machine and has been adding patents on a monthly basis for the machine or indications and processes.
      This link discusses BHRT's troubles.

      One note for those looking at CYTX...CYTX will likely be raising cash at some point soon as well, however they do have sales and a product on the market.

      • 1 Reply to dstdst2001
      • This is from a recent BHRT press release: "Bioheart Announces Commercial Order for TGI 1200(tm) Adult Stem Cell Isolation System for Use in Chronic Limb Ischemia Patients

        SUNRISE, Fla., Jan 14, 2009 (GlobeNewswire via COMTEX News Network) -- Bioheart, Inc. (Nasdaq:BHRT) announced today it has received a purchase order for a TGI 1200 System from Philadelphia BioMed Product Development Centre.*

        Bioheart's TGI 1200 System is a fully-automated, point-of-care system that recovers potentially regenerative cells from a patient's own fat in about an hour, with minimal operator intervention. No tissue pre-processing is required. The system, distributed by Bioheart under an exclusive license from Tissue Genesis, Inc., accepts adipose (fat) tissue from the same device used for liposuctioning the tissue from the patient. The compact desktop unit readily fits into any clinical environment and uses preconfigured disposables for quick and easy assembly."

1.39+0.02(+1.46%)Aug 26 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.